Klaus Dembowsky
Chief Executive Officer at amcure GmbH
Klaus Dembowsky active positions
| Companies | Position | Start | End |
|---|---|---|---|
amcure GmbH
 amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Chief Executive Officer | - | - |
Career history of Klaus Dembowsky
Former positions of Klaus Dembowsky
| Companies | Position | Start | End |
|---|---|---|---|
| SPEXIS AG | Chief Tech/Sci/R&D Officer | 2012-10-03 | - |
| Corporate Officer/Principal | 2009-11-16 | 2012-10-03 | |
| BAYER AG | Corporate Officer/Principal | - | - |
Ingenium Pharmaceuticals GmbH
 Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Corporate Officer/Principal | - | - |
Speedel Pharma AG
 Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Chief Executive Officer | - | - |
Training of Klaus Dembowsky
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Statistics
International
| Germany | 5 |
| Switzerland | 3 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Executive Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 5 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BAYER AG | Health Technology |
| SPEXIS AG | Health Technology |
| Private companies | 3 |
|---|---|
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Health Technology |
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
amcure GmbH
amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Health Technology |
- Stock Market
- Insiders
- Klaus Dembowsky
- Experience
